Seventure Partners is a leading European venture capital firm founded in 1997 and headquartered in Paris, France. It invests in innovative companies across life sciences (microbiome, health, nutrition, foodtech, biotech) and digital technologies (fintech, retailtech), from seed to growth stage.
Deal activity decreased year-over-year (4 deals in the last 12 months vs 6 prior). Average disclosed round size is $29.3M (across 40 rounds with reported amounts).
Portfolio
62
Fund Size
—
Top Stage
Series A
Last 12 Mo
6
Team
Isabelle de Cremoux
CEO and Managing Partner
Bruno Rivet
Senior Partner in the Digital Technologies/Sport
David Manjarres
Senior Partner - head of Digital Technologies team
Emmanuel Fiessinger
Senior Partner in the Lifesciences team
Pierre Aumeunier
Chief Financial Officer
Iain Wilcock
UK Venture Partner
Oxana Kukhaneva
Venture Partner
Thibault Canton
Partner
Jeanne Berron
Life Sciences Investment Associate
Arthur Bourgade
Analyst
Quang Lê
Analyst
Guillaume Echaudemaison
Tech VC
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Wultra | Series A | — | Jul 2026 |
 Standing Ovation | Series B | $28.5M | Mar 2026 |
| EErVimmune | Series A | $19.8M | Jan 2026 |
| TThe Sanctuary Group | Unknown | $5.8M | Jan 2026 |
 Tubulis | Series C | — | Oct 2025 |
| TTubulis GmbH | Series C | — | Oct 2025 |
| FFlexvelop | Growth | — | Mar 2025 |
 Karmen | Unknown | $9.4M | Jan 2025 |
 Animab | Series B | — | Jan 2025 |
 Fire1 | Unknown | $120M | Jan 2025 |
 bsport | Series B | — | Dec 2024 |
 Citryll | Series B | — | Dec 2024 |
| SSyroco | Series A | — | Dec 2024 |
 AENITIS TECHNOLOGIES | Unknown | — | Oct 2024 |
 Allozymes | Series A | $15M | May 2024 |
 YesWeHack | Series C | — | Jan 2024 |
| CComet Meetings | Series A | — | Jan 2024 |
 Eligo Bioscience | Series B | $30M | Dec 2023 |
| EEligo | Unknown | $30M | Dec 2023 |
| Fire1 | Unknown | $25M | Mar 2023 |
 Bcd Bioscience | Series A | $12M | Jan 2022 |
| TTubulis GmbH | Series B | — | Jan 2022 |
 Cytoki Pharma | Series A | $45M | May 2021 |
 PEP-Therapy | Series A | — | Apr 2021 |
 Hepster | Series A | $10M | Mar 2021 |
Top Co-Investors
Last updated: 8 September 2026